Vivos Therapeutics Files 8-K

TL;DR

Vivos Therapeutics filed an 8-K on Sept 18, 2024. Standard corporate update.

AI Summary

Vivos Therapeutics, Inc. filed an 8-K on September 18, 2024, reporting other events and financial statements. The company, formerly Vivos BioTechnologies, Inc., is incorporated in Delaware and headquartered in Littleton, Colorado.

Why It Matters

This filing provides updates on Vivos Therapeutics' corporate activities and financial reporting, which are important for investors to monitor the company's status.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for corporate events and financial statements, not indicating immediate significant risk.

Key Players & Entities

• Vivos Therapeutics, Inc. (company) — Registrant
• Vivos BioTechnologies, Inc. (company) — Former company name
• September 18, 2024 (date) — Date of earliest event reported
• Littleton, Colorado (location) — Principal executive offices
• Delaware (location) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share VVOS The NASDAQ Stock Mar

Filing Documents

• form8-k.htm (8-K) — 36KB
• ex99-1.htm (EX-99.1) — 24KB
• 0001493152-24-036942.txt ( ) — 241KB
• vvos-20240918.xsd (EX-101.SCH) — 3KB
• vvos-20240918_lab.xml (EX-101.LAB) — 33KB
• vvos-20240918_pre.xml (EX-101.PRE) — 24KB
• form8-k_htm.xml (XML) — 4KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 7921 Southpark Plaza , Suite 210 Littleton , Colorado 80120 (Address of principal executive offices) (Zip Code) (844) 672-4357 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share VVOS The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Information On September 18, 2024, Vivos Therapeutics, Inc. (the " Company ") issued a press release to announce receipt of an U.S. Food and Drug Administration 510(k) clearance to treat moderate to severe obstructive sleep apnea in children aged 6 to 17 using one of the Company's proprietary CARE oral medical devices. A copy of such press release is filed as Exhibit 99.1 to this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated September 18, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIVOS THERAPEUTICS, INC. Dated: September 18, 2024 By: /s/ Bradford Amman Name: Bradford Amman Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR